BiotechTube
Home/Pipeline/Pepticom‑IL17

Pepticom‑IL17

Plaque Psoriasis

Lead OptimizationActive

Key Facts

Indication
Plaque Psoriasis
Phase
Lead Optimization
Status
Active
Company
Pepticom

About Pepticom

AI‑powered platform that designs next‑generation therapeutic peptides, starting with an oral IL‑17 inhibitor for psoriasis.

View full company profile

Therapeutic Areas

ImmunologyDermatology

Other Plaque Psoriasis Drugs

DrugCompanyPhase
Piclidenoson (CF101)Can Fite BiopharmaPhase III
Psoriasis TrialClinical Investigation SpecialistsNot Specified
Encube-001Encube EthicalsPhase 1/2a
ZL-1102 (CB001)Crescendo BiologicsPhase 2
AX-158Artax BiopharmaPhase 2
NG-303Nanogen Pharmaceutical BiotechnologyPreclinical
JNJ-2113Johnson & JohnsonPhase 3
VTAMA® (tapinarof)Roivant SciencesApproved
WynzoraAlmirallMarketed
JNJ-81201887 (via Janssen)OmniAbApproved